Please assess the completion status of the following clinical trial:

Trial Title: Oxandrolone to Heal Pressure Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~SCREENING PHASE:~1. Male or female inpatient with SCI or equivalent spinal cord damage.~2. At least one Stage III or IV (including a severe wound, \<260cm2) pressure ulcer of the pelvic region.~TREATMENT PHASE:~1. documentation (through screening phase) of difficult to heal (defined as \<30% area reduction) or worsening status of the pressure ulcer for at least 28 days as inpatient (screening phase)~Exclusion Criteria:~SCREENING PHASE:~1. Persons who are candidates for and elect to have reconstructive flap surgery of the TPU;~2. Persons with known osteomyelitis who have not been, or refuse to be, adequately treated with appropriate antibiotic treatment for at least 6 weeks and/or appropriate surgical procedures, as determined by the patients' physician, as well as patients who have not had resolution of osteomyelitis after 3 months of antibiotic and/or surgical care.~3. Psychopathology (documentation in the medical record or history of self-abusive behavior specific to pressure ulcer healing which may or may not include major or minor psychiatric illness) that may conflict with study objectives;~4. Previously diagnosed active malignant disease;~5. Suspicion of skin cancer at the pressure ulcer site (a biopsy-negative patient is not excluded, nor is a biopsy-positive patient excluded after a curative excision of the lesion);~6. Radiation therapy in the pressure ulcer field at anytime during the patient's lifetime;~7. Life expectancy less than 12 months;~8. Nephrosis, hemodialysis or chronic ambulatory peritoneal dialysis therapy;~9. AIDS patients at immunological risk of infectious complications defined as any of the following: (1) CD4 count \<100 cells/ L or (2) CD4 count 100 to 200 cells/ L and WBC \< 4,000 cells/ L or (3) a confirmed viral load within the past 6 months;~10. Administration of oxandrolone or another anabolic agent (not including testosterone replacement therapy) within the past 6 months;~11. A known hypersensitivity to anabolic steroid medications (specifically oxandrolone);~12. Coronary athersclerosis with unstable angina pectoris or a history within the past 3 months of an acute myocardial event or decompensated congestive heart failure.~13. Inability or unwillingness of the subject or surrogate to provide informed consent.~TREATMENT PHASE:~1. TPU \>200 cm2 surface area of the pelvic region~2. Pressure ulcers with a clinical impression that are not expected to heal, such as those with: osteomyelitis (defined as persons with known osteomyelitis who have not been, or refuse to be, adequately treated with appropriate antibiotic treatment for at least 6 weeks and/or appropriate surgical procedures, as determined by the patients' physician, as well as patients who have not had resolution of osteomyelitis after 3 months of antibiotic and/or surgical care), sinus tracts suggestive of active osteomyelitis, communication to the synovial space, or other conditions;~3. Patient had flap surgery of the TPU during the Screening Phase;~4. Multiple full-thickness pressure ulcers that have a body surface area totaling \>500cm2;~5. Clinical and/or laboratory evidence suggestive of prostate cancer;~6. Elevated liver function tests (AST \>112 IU/L or bilirubin \>3mg/dl);~7. Diabetes mellitus with less than optimal glycemic control (HbA1c \>8.0%);~8. Received moderate (equivalent to prednisone 40 to 60 mg/d) or high dose (equivalent to prednisone \>60 mg/d) systemic corticosteroids for at least 4 weeks, immunosuppressive agents, anti-cancer agents, or any radiation therapy within 30 days prior to randomization or are likely to receive one of these therapies during study participation;~9. Initiating or continuing therapy with appetite stimulants (e.g., Megase);~10. Current pharmacological therapy for hepatitis B or C infection;~11. Pregnancy or lactating female;~12. Females of child-bearing potential who are unwilling to agree to abstinence from sexual intercourse or the use of two reliable forms of contraception during the study; males unwilling to agree to abstinence from sexual intercourse or use of a condom during the study;~13. Expected use of oral anticoagulants (e.g. warfarin sodium) during the treatment phase;~14. Hypercalcemia;~15. Coronary athersclerosis with unstable angina pectoris or a history within the past 3 months of an acute myocardial event or decompensated congestive heart failure;~16. Participation in another active treatment clinical trial;~17. Inability or unwillingness of the subject or surrogate to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): oxandrolone
- 2 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).